Oncology News

Oncology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Stephenson AJ et al. – The pathologic features and outcome of patients treated at low PSA levels are favorable and similar for patients with PSA < or = 2.5 versus 2.6–4.0. However, > 50% of the former have potentially biologically unimportant cancer. We failed to identify a therapeutic benefit to the diagnosis of cancers below accepted PSA thresholds for biopsy.


   

Today in Oncology...keeping you current

Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09

What comes after docetaxel
Der Urologe, 11/18/09

Today in Prostate...keeping you current

Is statin use associated with prostate cancer aggressiveness
BJU International, 11/09/09

Risk of dying from prostate cancer in men randomized to screening
Cancer, 10/13/09

What comes after docetaxel
Der Urologe, 11/18/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address